US2710860A - Nikethamide adenylate - Google Patents

Nikethamide adenylate Download PDF

Info

Publication number
US2710860A
US2710860A US779209A US77920947A US2710860A US 2710860 A US2710860 A US 2710860A US 779209 A US779209 A US 779209A US 77920947 A US77920947 A US 77920947A US 2710860 A US2710860 A US 2710860A
Authority
US
United States
Prior art keywords
solution
adenylate
adenylic
adenylic acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US779209A
Inventor
Simon L Ruskin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHYSICLOGICAL CHEMICALS Co
PHYSICLOGICAL CHEMICALS COMPAN
Original Assignee
PHYSICLOGICAL CHEMICALS COMPAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25115669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US2710860(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PHYSICLOGICAL CHEMICALS COMPAN filed Critical PHYSICLOGICAL CHEMICALS COMPAN
Priority to US779209A priority Critical patent/US2710860A/en
Application granted granted Critical
Publication of US2710860A publication Critical patent/US2710860A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Definitions

  • Claim. (Cl. 260-4115) My invention relates to amine compounds and especially to amino acid compounds, of the individual nucleotide known as adenylic acid, and to a process for manufacturing such compounds.
  • amino acid compounds of adenylic acid which are characterized by improved solubility and modified therapeutic activity, as explained more fully hereinafter.
  • Adenylic nucleotide therapy is particularly eilective in the stabilization of the circulation, both in high and low blood pressure conditions.
  • high blood pressure there is usually a vase-constriction with elevation of diastolic pressure.
  • Adenylic acid has the elfect of lowering the diastolic pressure by counteracting the vaso-constriction through vase-dilatation.
  • low blood pressure the adenylic acid, through its improvement of muscular metabolism, increases the muscular tone of the heart and improves the blood pressure level.
  • the amine compounds of adenylic acid counteract these disturbances by slowing the speed of utilization of the adenylic nucleotide, thereby diminishing the etfect of the disturbing factors, and thus provide a less intense but longer-lasting adenylic effect.
  • the adenylic acid is made much more suitable for injection not only because of the decrease in acidity but generally also because of the improvement in the solubility.
  • the monoeth-anolamiue salt of adenylic acid has a pH close to neutral, is much more soluble in water than adenylic acid, and is non-irritating on injection.
  • the amine component of the amine compounds of adenylic acid of the present invention may or may not in itself have therapeutic activity.
  • the amine base acts to reduce the rate of the adenylic acid eifect without adding any particular therapeutic activity to the compound, there resulting a sustained and prolonged physiologic adenylic action.
  • amino acids like those obtained by hydrolysis of proteins, vitamin B- components, and other amine compounds referred to elsewhere herein, contribute their own specific effects while at the same time moderating the action of the adenylic nucleotide.
  • the amines whose adenylic acid compounds are included within the scope of the present invention are of various types. Important physiological ellects are obtained when the adenylic acid is combined with various amino acids, and particularly with arginine, histidine, lysine, tryptophane, gylcine, valine, cystine and cysteine. These compounds enhance the energy potential of the adenylic nucleotide and apparently facilitate the use of the energy-rich iminoalkylol phosphate bond which is present in adenylic acid.
  • adenylic acid is combined with amines of such character that the normal adenylic action is modified or retarded; or the physiological action of the amine, where the same has physiological activity, is modified.
  • the dosage of the amine adenylates embraced by the present invention can correspond to that of adenylic acid or of the amine, whichever is the lower. however, the dosage of the adenylate radical, or of the physiologically active amine radical, can be somewhat lower than the normal dosage for such radical when administered without the other, where the action of the two radicals is similar; where, however, they act antagonistically somewhat larger dosages can be safely administered.
  • the product has a tendency to darken; heating of the solution above 50 C. should therefore be avoided.
  • Alkylated glucosamines like methyl glucosamine, can be used instead of glucosamine to produce the corresponding alkyl glucosarn-ine adenylate.
  • Example 2 -Histldine adcrzylate To 10 grams of adenylic acid in 100 cc. water there were added 44 cc. of a 5% histidine solution equivalent to 2.2 histidine. Solution of the adenylic acid was slow but when heated to about 60 C. it dissolved rapidly. The solution was filtered through a carbon-coated filter to clear it of a slight turbidity. A little ethyl alcohol was added until a slight permanent turbidity was obtained. A crystalline precipitate formed over a period of several days. Addition of more alcohol increased the yield of crystals of histidine adenylate.
  • Example 3.Mn0ethan0la1nine adenylate Ten grams of monoethanolamine were dissolved in water and made up to a volume of 500 cc. with water. To 88 cc. of this solution, equivalent to 1.76 g. monoethanolamine, were added 10 grams of adenylic acid. Most of the adenylic acid went into solution. A little ethyl alcohol was added until a slight turbidity was obtained. After several days the solution was filtered from the small residue. To the filtrate there was added a little butyl alcohol, and the mixture allowed to stand in the desiccator to evaporate. Hair-like crystals formed on the sides of the beaker. The product appeared to be slightly deliquescent.
  • Example 4.Clt0line adenylate 1500 g. choline chloride were dissolved in 6000 cc. methyl alcohol to which were then added 2750 g. silver carbonate. The mixture was stirred well, the silver carbonate at bottom of solution being stirred up, and then allowed to stand for several hours in the dark. The mixture was filtered through a carbon-coated filter, and the residue washed with methyl alcohol. The total volume of choline carbonate solution was 8650 cc.
  • Example .H istamine adenylate To a solution of 111 mg. of histamine (M/l000) in a few cc. of water, there were added 694 mg. of adenylic acid (M/500). The mixture was shaken until clear and then made up to 16 cc. with water, thereby yielding a 5% solution of histamine adenylate.
  • Example 7 Acetylch0line adenylate 0.6 g. of adenylic acid were dissolved in cc. of water to which had been added 1.5 cc. of normal NaOH solution. To this there was added 0.3 g. of acetylcholine hydrochloride dissolved in about 2 cc. of water. The resulting solution was still acid. A few drops of normal sodium hydroxide solution were added to bring the solution to neutral. The final volume of the solution is about cc. It was unnecessary to remove the formed sodium chloride as its presence is unobjectionable in a solution prepared for injection.
  • Example 9 Pyridine adenylate 2 grams of adenylic acid and 0.51 cc. of pyridine (equimolecular proportions) were added to cc. of hot water in which both reagents dissolved almost completely. The solution was filtered hot through filter paper. The filtrate was clear. On cooling, methyl alcohol was added to the filtrate until a permanent turbidity was obtained. The solution was placed in a desiccator and on further evaporation therein, crystals of the salt were obtained. The addition of propyl alcohol to the thin syrup resulted in better crystals. The crystals were filtered and washed with two portions of 10 cc. of propyl alcohol.
  • Example 10 Cystine adenylute 2 grams of adenylic acid (2 rnols) and 0.7 g. of cystine (1 mol) were heated in cc. of water to about C. The solution was filtered hot from an insoluble residue which weighed 0.8 g. Crystals formed in the filtrate on cooling. After several days the crystals of cystine adenylate were filtered and dried. Weight of crystals: 0.9 g.
  • Example ] 1.Trypt0pl1ane allenylate 2 grams of adenylic acid (1 mol) and 1.2 grams of tryptophane (1 mol) were heated together in about 50 cc. of water to about C. The reagent is dissolved almost completely. The solution was filtered hot from the very small residue. On cooling, crystals of the salt formed and were filtered and dried. Weight of crystals: 2.4 g.
  • Example 1Z.Urea adenylate 1 gram of adenylic acid (1 mol) and 0.17 gram of urea (1 mol) were heated in about 50 cc. of water to about 60 C.
  • the reagents dissolved completely for a residue which weighed 0.2 g.
  • the solution was filtered and the filtrate evaporated to about 15 cc. Crystals of the salt formed and after several days were filtered and dried. Weight of crystals: 0.6 g.
  • Example 13 Pr0mmine adenylate 0.5 g. of protamine sulfate was freed from sulfate radical by precipitation of the latter with barium hydroxide solution (10 per cent). About 20 per cent of the protamine sulfate was found to be actually sulfate. To the filtrate, there was added 0.85 g. of adenylic acid partially dissolved in 50 cc. of hot water. On slight heating with the protamine filtrate the suspended adenylic acid went into solution. The solution was concentrated in vacuo to a thin syrup of about 10 cc. To a part of this syrup there was added 20 cc. of absolute ethyl alcohol and the mixture evaporated in a desiccator over calcium chloride. There was obtained a dried, glistening white residue which appeared to be crystalline.
  • Example 14 Lysine adenylate 350 mg. adenylic acid and 200 mg. lysine hydrochloride were suspended in 44 cc. water. On addition of 1 cc. normal sodium hydroxide, complete solution took place at room temperature. After vacuum desiccation a white amorphous powder was obtained.
  • Example 15 -Arginine adenylate 35 mg. adenylic acid and 210 mg. arginine hydrochloride were suspended in 4 cc. water. On addition of 1 cc. normal sodium hydroxide, a colorless solution resulted which was placed in a vacuum desiccator. On complete evaporation a white amorphous powder was obtained.
  • adenylates of the other amine compounds referred to above can be prepared.
  • a non-toxic base like sodium, potassium or calcium hydroxides or carbonates should be added to neutralize the acid.
  • the above compounds may be administered by mouth but in general are preferably administered by injection intramuscularly.
  • the adenylates are advantageously suspended in a mixture of beeswax and peanut oil. Suspensions in these media are especially desirable for patients who are sensitive to the circulatory influence of the adenylates.
  • other oils and watermiscible, non-toxic organic solvents can be used, and likewise other waxy substances, such as a mixture of propylene glycol and cholesterol, or a mixture of peanut or sesame with cholesterol.
  • suspending agents can be used advantageously also for sodium and potassium adenylates whether used alone or in admixture with any of the amine adenylates above disclosed. Where an increased rate of absorption of the adenylic radical is desired, suspensions of creatin adenylate and creatinine adenylate in an aqueous medium have proved highly effective. These compounds can be prepared as above by heating combining proportions of adenylic acid and creatin or creatinine in an aqueous solvent, followed by evaporation.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States atent FLT/W359 Patented June 141*, 1955 NIKETHAMEDE ADENYLATE Simon L. Ruskin, New York, N. Y., assignor to Physiological Chemicals Company, New Rochelle, N. Y., a corporation of New York No Drawing. Application ()ctoher ll), 1947, Serial No. 779,209
1 Claim. (Cl. 260-4115) My invention relates to amine compounds and especially to amino acid compounds, of the individual nucleotide known as adenylic acid, and to a process for manufacturing such compounds. I
it is the general object of the present invention to provide therapeutic preparations consisting of or containing amine compounds of adenylic acid by whose use certain undesirable effects accompanyiing the use of free adenylic acid are avoided, while at the same time the therapeutic activity of certain other substances of amine character and particularly of amino acids, can be taken advantage of.
More specifically, it is an object of the invention to provide amino acid compounds of adenylic acid which are characterized by improved solubility and modified therapeutic activity, as explained more fully hereinafter.
It is a still further object of the invention to provide more or less neutral compounds of adenylic acid which are practically non-irritating on injection.
Other objects and advantages of the invention will appear as the following more detailed description of the same proceeds.
Adenylic nucleotide therapy is particularly eilective in the stabilization of the circulation, both in high and low blood pressure conditions. In the case of high blood pressure there is usually a vase-constriction with elevation of diastolic pressure. Adenylic acid has the elfect of lowering the diastolic pressure by counteracting the vaso-constriction through vase-dilatation. In the case of low blood pressure the adenylic acid, through its improvement of muscular metabolism, increases the muscular tone of the heart and improves the blood pressure level.
It is known that on the injection of certain known adenylic compounds like adenylic acid itself and sodium adenylate, there occurs a peripheral vascular dilatation accompanied by flushing of the skin and sudden drop in blood pressure which subsequently rises so that the pulse pressure is increased. However, the immediate vascular reaction is in some cases sufiicient to cause syncopy and accompanying dilatation of the coronary artery, while increase of the flow of blood to the heart muscles gives the patient Who has a labile vasomotor mechanism a sense of tightness in the chest which may be distressing, despite the fact that the patient is in no real danger. With rising blood pressure this feeling disappears. This undesirable reaction has militated against a wider use of the adenylic nucleotide.
I have found that certain of the amine compounds of adenylic acid counteract these disturbances by slowing the speed of utilization of the adenylic nucleotide, thereby diminishing the etfect of the disturbing factors, and thus provide a less intense but longer-lasting adenylic effect. By combination with an amine, the adenylic acid is made much more suitable for injection not only because of the decrease in acidity but generally also because of the improvement in the solubility. Thus, the monoeth-anolamiue salt of adenylic acid has a pH close to neutral, is much more soluble in water than adenylic acid, and is non-irritating on injection.
The amine component of the amine compounds of adenylic acid of the present invention may or may not in itself have therapeutic activity. Thus, in the case of the mono-, di-, and tri-ethanolamine, propanolamine and similar non-toxic alkylolamine salts, and the pyridine salt or adenylic acid, the amine base acts to reduce the rate of the adenylic acid eifect without adding any particular therapeutic activity to the compound, there resulting a sustained and prolonged physiologic adenylic action. On the other hand, amino acids, like those obtained by hydrolysis of proteins, vitamin B- components, and other amine compounds referred to elsewhere herein, contribute their own specific effects while at the same time moderating the action of the adenylic nucleotide.
The amines whose adenylic acid compounds are included within the scope of the present invention are of various types. Important physiological ellects are obtained when the adenylic acid is combined with various amino acids, and particularly with arginine, histidine, lysine, tryptophane, gylcine, valine, cystine and cysteine. These compounds enhance the energy potential of the adenylic nucleotide and apparently facilitate the use of the energy-rich iminoalkylol phosphate bond which is present in adenylic acid. Another group of amines which form therapeutically desirable compounds with adenylic acid are creatin, creatinine, creatinine-urea, alkaloid hormones containing amino groups, urea, glutathione, and the amino compounds, as a group, contained in liver extract. The invention contemplates the production also of adenylates of other amino compounds like the protamines, glucosamine, succinarnide and pyridine.
In accordance with the invention, therefore, adenylic acid is combined with amines of such character that the normal adenylic action is modified or retarded; or the physiological action of the amine, where the same has physiological activity, is modified.
The dosage of the amine adenylates embraced by the present invention can correspond to that of adenylic acid or of the amine, whichever is the lower. however, the dosage of the adenylate radical, or of the physiologically active amine radical, can be somewhat lower than the normal dosage for such radical when administered without the other, where the action of the two radicals is similar; where, however, they act antagonistically somewhat larger dosages can be safely administered.
In preparing the compounds of the present invention, the amine can be treated with adenylic acid in combining proportions in aqueous solution, preferably with the aid of heat. The amine adenylate canbe recovered by evaporation or by precipitation by a water-miscible organic liquid in which the adenylate is relatively insoluble, like lower aliphatic alcohols, acetone, etc. Where the amine is employed in the form of its acid salt, a neutralizing agent like an alkali metal base can be added to bind the acid. Where the amine chloride is used, the chlorine can be bound also by silver.
The invention will be described in further detail by way of the following examples which are presented for purposes of illustration and not as indicating the scope of the invention.
Example 1.Gluc0samine adenylate 120 g. glucosaminhydrochloride were dissolved in 2000 cc. water, and a solution of 80 g. silver carbonate in 1500 cc. water containing 40 cc. concentrated sulfuric acid was added. Glucosaminsulfate was formed and the solution was kept acid so as to avoid reduction of silver salt and oxidation of the glucosamin. The mixture was stirred and shaken, allowed to stand an hour in the dark, then filtered through a Biichner filter. The filterat'e was cloudy In general,
with some colloidal silver chloride and was heated to near boiling to precipitate the silver chloride. After standing in the dark overnight, it was filtered on an uncoated Biichner filter. The small precipitate was not washed. The filtrate was clear and a few drips of it gave a negative test for chloride with silver nitrate.
Hydrogen sulfide was passed through the filtrate to precipitate out traces of silver and the silver sulfide filtered off. To the hot filtrate was added a little less than 220 g. of Ba(OH)2.8H2O in 1000 cc. hot water and all residual sulfate ions removed by further quantities of the base until the exact amount of barium hydroxide was added. as shown by testing small portions of filtrate with a drop of N/H2SO4. (The use of excess of barium hydroxide is to be avoided as it may affect the glucosamine.) Test samples may be combined with the main portion to avoid loss.
The filtrate fromthe barium sulfate was evaporated in vacuo and made up to a volume of 4800 cc. with water.
To 1640 cc. of this glucosamin solution, equivalent to 40.96 g. glucosamine hydrochloride, were added 66 g. adenylic acid were dissolved in 1000 cc. hot water, and the mixture cooled, filtered through a carbon-covered filter, evaporated in vacuo to about 150 cc., poured into a small beaker, the flask washed with 50 cc. warm water and this combined with the main portion. Ethyl alcohol was stirred in until permanent turbidity was obtained, and the mixture was then placed in a desiccator. (It is better to dissolve the adenylic acid in water before adding to the glucosaminc solution in order to avoid warming.)
On evaporation, hair-like crystals appeared on the sides of the beaker, but the main portion was a hard mass.
The product has a tendency to darken; heating of the solution above 50 C. should therefore be avoided.
Alkylated glucosamines, like methyl glucosamine, can be used instead of glucosamine to produce the corresponding alkyl glucosarn-ine adenylate.
Example 2.-Histldine adcrzylate To 10 grams of adenylic acid in 100 cc. water there were added 44 cc. of a 5% histidine solution equivalent to 2.2 histidine. Solution of the adenylic acid was slow but when heated to about 60 C. it dissolved rapidly. The solution was filtered through a carbon-coated filter to clear it of a slight turbidity. A little ethyl alcohol was added until a slight permanent turbidity was obtained. A crystalline precipitate formed over a period of several days. Addition of more alcohol increased the yield of crystals of histidine adenylate.
Example 3.Mn0ethan0la1nine adenylate Ten grams of monoethanolamine were dissolved in water and made up to a volume of 500 cc. with water. To 88 cc. of this solution, equivalent to 1.76 g. monoethanolamine, were added 10 grams of adenylic acid. Most of the adenylic acid went into solution. A little ethyl alcohol was added until a slight turbidity was obtained. After several days the solution was filtered from the small residue. To the filtrate there was added a little butyl alcohol, and the mixture allowed to stand in the desiccator to evaporate. Hair-like crystals formed on the sides of the beaker. The product appeared to be slightly deliquescent.
Example 4.Clt0line adenylate 1500 g. choline chloride were dissolved in 6000 cc. methyl alcohol to which were then added 2750 g. silver carbonate. The mixture was stirred well, the silver carbonate at bottom of solution being stirred up, and then allowed to stand for several hours in the dark. The mixture was filtered through a carbon-coated filter, and the residue washed with methyl alcohol. The total volume of choline carbonate solution was 8650 cc.
200 cc. methyl alcohol were added to 10 g. adenylic acid. To the mixture there were added 23 cc. of the choline carbonate solution as prepared above, equivalent to about 4.0 g. choline chloride. Since the adenylic did not all go into solution, a little water was added and the solution heated on the hot water bath. The product was iltered through a carbon-coated filter and the filtrate placed in the desicccator to evaporate. The hair-like crystals which formed on the sides of the beaker were very deliquescent.
Example .H istamine adenylate To a solution of 111 mg. of histamine (M/l000) in a few cc. of water, there were added 694 mg. of adenylic acid (M/500). The mixture was shaken until clear and then made up to 16 cc. with water, thereby yielding a 5% solution of histamine adenylate.
Example 6.Glutathi0ne adenylate 0.35 g. of adenylic acid (M/lOOO) were dissolved in 20 cc. of hot water. To this there were added 0.30 g. of glutathione (M/ 1000). The clear reaction solution was then concentrated in vacuo. On standing for some time in the ice chest the solution yielded white crystals of the glutathione adenylate.
Example 7.Acetylch0line adenylate 0.6 g. of adenylic acid were dissolved in cc. of water to which had been added 1.5 cc. of normal NaOH solution. To this there was added 0.3 g. of acetylcholine hydrochloride dissolved in about 2 cc. of water. The resulting solution was still acid. A few drops of normal sodium hydroxide solution were added to bring the solution to neutral. The final volume of the solution is about cc. It was unnecessary to remove the formed sodium chloride as its presence is unobjectionable in a solution prepared for injection.
Example 8.Nikellzamide adenylal-e 1.95 g. of adenylic acid were partially dissolved in 100 cc. of warm water and 1 g. of nil-:ethamide added to the mixture. The latter was stirred and the two reagents dissolved almost completely. The solution was filtered with suction from a small residue. The filtrate was evaporated in vacuo to about 10 cc., when crystals began to form. The syrup was transferred to a small beaker and placed in the desiccator. After standing for three days the crystals were filtered free of the mother liquor.
Example 9.Pyridine adenylate 2 grams of adenylic acid and 0.51 cc. of pyridine (equimolecular proportions) were added to cc. of hot water in which both reagents dissolved almost completely. The solution was filtered hot through filter paper. The filtrate was clear. On cooling, methyl alcohol was added to the filtrate until a permanent turbidity was obtained. The solution was placed in a desiccator and on further evaporation therein, crystals of the salt were obtained. The addition of propyl alcohol to the thin syrup resulted in better crystals. The crystals were filtered and washed with two portions of 10 cc. of propyl alcohol.
Example 10.Cystine adenylute 2 grams of adenylic acid (2 rnols) and 0.7 g. of cystine (1 mol) were heated in cc. of water to about C. The solution was filtered hot from an insoluble residue which weighed 0.8 g. Crystals formed in the filtrate on cooling. After several days the crystals of cystine adenylate were filtered and dried. Weight of crystals: 0.9 g.
Example ]1.Trypt0pl1ane allenylate 2 grams of adenylic acid (1 mol) and 1.2 grams of tryptophane (1 mol) were heated together in about 50 cc. of water to about C. The reagent is dissolved almost completely. The solution was filtered hot from the very small residue. On cooling, crystals of the salt formed and were filtered and dried. Weight of crystals: 2.4 g.
Example 1Z.Urea adenylate 1 gram of adenylic acid (1 mol) and 0.17 gram of urea (1 mol) were heated in about 50 cc. of water to about 60 C. The reagents dissolved completely for a residue which weighed 0.2 g. The solution was filtered and the filtrate evaporated to about 15 cc. Crystals of the salt formed and after several days were filtered and dried. Weight of crystals: 0.6 g.
Example 13.Pr0mmine adenylate 0.5 g. of protamine sulfate was freed from sulfate radical by precipitation of the latter with barium hydroxide solution (10 per cent). About 20 per cent of the protamine sulfate was found to be actually sulfate. To the filtrate, there was added 0.85 g. of adenylic acid partially dissolved in 50 cc. of hot water. On slight heating with the protamine filtrate the suspended adenylic acid went into solution. The solution was concentrated in vacuo to a thin syrup of about 10 cc. To a part of this syrup there was added 20 cc. of absolute ethyl alcohol and the mixture evaporated in a desiccator over calcium chloride. There was obtained a dried, glistening white residue which appeared to be crystalline.
Example 14.Lysine adenylate 350 mg. adenylic acid and 200 mg. lysine hydrochloride were suspended in 44 cc. water. On addition of 1 cc. normal sodium hydroxide, complete solution took place at room temperature. After vacuum desiccation a white amorphous powder was obtained.
Example 15.-Arginine adenylate 35 mg. adenylic acid and 210 mg. arginine hydrochloride were suspended in 4 cc. water. On addition of 1 cc. normal sodium hydroxide, a colorless solution resulted which was placed in a vacuum desiccator. On complete evaporation a white amorphous powder was obtained.
In similar fashion the adenylates of the other amine compounds referred to above can be prepared. As indicated by certain of the examples, where the amine is used in the form of an acid salt, like the hydrochloride, enough of a non-toxic base, like sodium, potassium or calcium hydroxides or carbonates should be added to neutralize the acid.
The above compounds may be administered by mouth but in general are preferably administered by injection intramuscularly. I have found that where it is desirable to delay the rate of absorption of the adenylic radical, the adenylates are advantageously suspended in a mixture of beeswax and peanut oil. Suspensions in these media are especially desirable for patients who are sensitive to the circulatory influence of the adenylates. In place of the mixture of beeswax and oil, other oils and watermiscible, non-toxic organic solvents can be used, and likewise other waxy substances, such as a mixture of propylene glycol and cholesterol, or a mixture of peanut or sesame with cholesterol. These suspending agents can be used advantageously also for sodium and potassium adenylates whether used alone or in admixture with any of the amine adenylates above disclosed. Where an increased rate of absorption of the adenylic radical is desired, suspensions of creatin adenylate and creatinine adenylate in an aqueous medium have proved highly effective. These compounds can be prepared as above by heating combining proportions of adenylic acid and creatin or creatinine in an aqueous solvent, followed by evaporation.
I claim:
Nikethamide adenylate.
Degering: Outline of Organic Nitrogen Compounds, 1945, page 615-616 (2 pp.).

Claims (1)

1. NIKETHAMIDE ADENYLATE.
US779209A 1947-10-10 1947-10-10 Nikethamide adenylate Expired - Lifetime US2710860A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US779209A US2710860A (en) 1947-10-10 1947-10-10 Nikethamide adenylate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US779209A US2710860A (en) 1947-10-10 1947-10-10 Nikethamide adenylate

Publications (1)

Publication Number Publication Date
US2710860A true US2710860A (en) 1955-06-14

Family

ID=25115669

Family Applications (1)

Application Number Title Priority Date Filing Date
US779209A Expired - Lifetime US2710860A (en) 1947-10-10 1947-10-10 Nikethamide adenylate

Country Status (1)

Country Link
US (1) US2710860A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152116A (en) * 1960-05-25 1964-10-06 Sigma Chem Co Tris (hydroxy methyl) amino methane salts of nucleotides
US3478015A (en) * 1966-11-14 1969-11-11 Yuki Gosei Yakuhin Kogyo Kk Process for reacting amino acid and an active carbonyl sugar in a polyhydric alcohol
US3853845A (en) * 1971-08-18 1974-12-10 Icn Pharmaceuticals 5-n-aminoacyl-5-aminouridines
DE2513193A1 (en) * 1974-04-02 1975-10-16 Marxer Spa D-GLYCOSAMINE SALT WITH THERAPEUTIC EFFECT
US3920026A (en) * 1972-03-07 1975-11-18 Liggett & Myers Inc Tobacco with flavor enhancer
US3993639A (en) * 1974-02-08 1976-11-23 Roland Yves Mauvernay Heptaminol adenosine-5'-monophosphate
DE3990820T1 (en) * 1988-07-19 1990-07-19 Serobiologiques Lab Sa LIGHT PROTECTION AGENT FOR SKIN CELLS BASED ON NUCLEIC ACIDS AND / OR THEIR DERIVATIVES
DE3990820C2 (en) * 1988-07-19 2001-02-15 Lab Serobiologiques Pulnoy Light stabilizers for skin cells based on ribonucleic acids and derivatives thereof, as well as derivatives of ribonucleotides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2089227A (en) * 1933-01-26 1937-08-10 Frances R Ruskin Quinine compounds of nucleo proteins and process for their production
US2417841A (en) * 1944-06-21 1947-03-25 Frances R Ruskin Nucleotide compounds of components of vitamin b complex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2089227A (en) * 1933-01-26 1937-08-10 Frances R Ruskin Quinine compounds of nucleo proteins and process for their production
US2417841A (en) * 1944-06-21 1947-03-25 Frances R Ruskin Nucleotide compounds of components of vitamin b complex

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152116A (en) * 1960-05-25 1964-10-06 Sigma Chem Co Tris (hydroxy methyl) amino methane salts of nucleotides
US3478015A (en) * 1966-11-14 1969-11-11 Yuki Gosei Yakuhin Kogyo Kk Process for reacting amino acid and an active carbonyl sugar in a polyhydric alcohol
US3853845A (en) * 1971-08-18 1974-12-10 Icn Pharmaceuticals 5-n-aminoacyl-5-aminouridines
US3920026A (en) * 1972-03-07 1975-11-18 Liggett & Myers Inc Tobacco with flavor enhancer
US3993639A (en) * 1974-02-08 1976-11-23 Roland Yves Mauvernay Heptaminol adenosine-5'-monophosphate
DE2513193A1 (en) * 1974-04-02 1975-10-16 Marxer Spa D-GLYCOSAMINE SALT WITH THERAPEUTIC EFFECT
US4157440A (en) * 1974-04-02 1979-06-05 Marxer S.P.A. Therapeutically active d-glucosamine salts
DE3990820T1 (en) * 1988-07-19 1990-07-19 Serobiologiques Lab Sa LIGHT PROTECTION AGENT FOR SKIN CELLS BASED ON NUCLEIC ACIDS AND / OR THEIR DERIVATIVES
DE3990820C2 (en) * 1988-07-19 2001-02-15 Lab Serobiologiques Pulnoy Light stabilizers for skin cells based on ribonucleic acids and derivatives thereof, as well as derivatives of ribonucleotides

Similar Documents

Publication Publication Date Title
SU1272992A3 (en) Method of producing 9-(3,4-dioxybutyl)-guanine
US2710860A (en) Nikethamide adenylate
US2994640A (en) Anti-inflammatory therapy with purine molecular compounds
US2539483A (en) Urea ascorbate and complexes containing the same and process for their manufacture
US2575344A (en) Dihydroxypropyl theophylline
US3830824A (en) Physiological organic acid silver allantoinates
KR840000702B1 (en) Process for preparing vincamine saccharinate
US2417841A (en) Nucleotide compounds of components of vitamin b complex
Austin et al. The Preparation of Two New Crystalline Aldohexoses, l-Allose and l-Altrose, from l-Ribose by the Cyanohydrin Reaction1, 2, 3
US2389582A (en) Compounds of 2-sulphanilamido-5-carboxythiazole with vasoconstrictors and their solutions
US2606903A (en) Ascorbic acid addition compound of sulfathiazole
US3019226A (en) Piperazine salt of phytic acid
JPS6028811B2 (en) Novel aluminum compound, its production method, and therapeutic agent for phosphate stone disease containing this compound
US2434625A (en) Preparation of alkali metal ascorbates
US2654735A (en) Process for the production of derivatives of 9-polyhydroxyalkylisoalloxazines and products obtained
EA026192B1 (en) Fe(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS
NO143084B (en) DEPARTMENT FOR SHALL REMOVAL OF MARINE CANCER, SPECIAL ANTARCTIC KRILL.
EP0650725A1 (en) Compositions containing salts of L-2-oxothiazolidine-4-carboxylic acid and their use for stimulating intracellular glutathione
US2800426A (en) Stable khellin solutions and method of preparing same
US3104203A (en) Composition of matter containing procaine adenylate
US2669563A (en) Bismuth salt of penicillin
US2752285A (en) Process for the production of at least approximately neutral solutions of substituted xanthines
US3845205A (en) 2-loweralkylthioadenosines
EP0200527A2 (en) Norfloxacin salt
Proskouriakoff Some Salts of Levulinic Acid1